what a joke.
we are talking about 10% dilution. We did more than 10% increase in our market cap on a single day several days last week. Just off market action. This is a pretty naive comment.
Management have been extremely astute in getting this done as an all scrip deal with next to no dilution. If it was $93M cash, well that would be a challenge but this is nothing. Any one of these verticals could justify a unicorn market cap. Have you had a look at some of the regulatory status. Some of these have completed Phase 2 clinical trials! We have a Billion dollar market cap off our OSA Phase 2A trial!!!
And for some pretty important conditions like glaucoma, IBS etc. I think this will transpire to be an incredible acquisition and as usual the Australian market has completely missed the ball
- Forums
- ASX - By Stock
- IHL
- Ann: Incannex to Acquire APIRx Pharmaceuticals
Ann: Incannex to Acquire APIRx Pharmaceuticals, page-51
-
- There are more pages in this discussion • 410 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online